| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-01-21 | Halozyme Therapeutics (USA - CA) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-01-21 | Medivir (Sweden) | nomination |
Infectious diseases | Nomination | ||
| 2015-01-21 | Sucampo Pharmaceuticals (USA - MD) | nomination |
Nomination | |||
| 2015-01-21 | SGS (Switzerland) | nomination |
Technology - Services | Nomination | ||
| 2015-01-21 | SGS (Switzerland) | resignation |
Technology - Services | Resignation | ||
| 2015-01-21 | Celgene (USA - NJ) Zymeworks (Canada) | bi-specific antibody therapeutics enabled using Zymeworks’ proprietary Azymetric™ platform | R&D licensing commercialisation |
Cancer - Oncology | Licensing agreement | |
| 2015-01-21 | MedImmune (USA - global biologics arm of AstraZeneca (UK) National Cancer Institute (USA) | immunotherapy and tumor targeted therapies including MEDI4736 (PD-L1), MEDI0680 (PD-1), tremelimumab (CTLA-4) and MEDI6469 (mOX40) | R&D |
Cancer - Oncology | R&D agreement | |
| 2015-01-20 | Valneva (France) BliNK Therapeutics (UK) | BliNK Biomedical | establishment of a new subsidiary in the EU |
Technology - Services | Establishment of a new subsidiary in the EU | |
| 2015-01-20 | BMS (USA - NY) | nomination |
Nomination | |||
| 2015-01-20 | Nerviano Medical Sciences Group (Italy) Tiziana Life Sciences (UK) | milciclib | breast cancer, hepatocellular carcinoma | licensing |
Cancer - Oncology | Licensing agreement |
| 2015-01-20 | Affimed (Germany) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-01-19 | Evotec (Germany) C4X Discovery (UK) | Orexin-1 selective inhibitors | addictive disorders | R&D |
R&D agreement | |
| 2015-01-19 | Addex Therapeutics (Switzerland) Dystonia Medical Research Foundation (USA - IL) | dipraglurant | dystonia | collaboration |
Neurological diseases | Collaboration agreement |
| 2015-01-19 | Vect-Horus (France) Sanofi (France) | proprietary technology to transport therapeutic antibodies into the brain | collaboration |
Neurodegenerative diseases | Collaboration agreement | |
| 2015-01-15 | Evotec (Germany) J&J (USA - NJ) | new targets for Alzheimer’s disease drug discovery and development | Alzheimer’s disease | R&D |
Neurodegenerative diseases | Milestone |
| 2015-01-15 | Sanofi (France) Boehringer Ingelheim (Germany) | therapeutic monoclonal antibodies | production maufacturing |
Production agreement | ||
| 2015-01-15 | Seres Therapeutics (USA - MA) | nomination |
Metabolic diseases - Digestive diseases - Infectious diseases | Nomination | ||
| 2015-01-14 | Oxford BioTherapeutics (UK) Boehringer Ingelheim (Germany) | novel cancer antibody targets | R&D licensing |
Cancer - Oncology | Exercise of an option agreement | |
| 2015-01-14 | Treeway (The Netherlands) Uniqure (The Netherlands) | ALS gene therapy | amyotrophic lateral sclerosis | licensing collaboration |
Neurodegenerative diseases - Rare diseases | Licensing agreement |
| 2015-01-13 | Cellectis (France) Ohio State University (USA - OH) | chimeric antigen receptor (CAR) technology targeting multiple myeloma cells | multiple myeloma | licensing |
Cancer - Oncology | Licensing agreement |
